Systemic treatment of vulvar cancer

References

• Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S7-27
   PubMed Web of Science ®Google Scholar
• Hampl M, Deckers-Figiel S, Hampl JA, et al. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 2008;109(3):340-5
   Google Scholar
• Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;113(4):917-24
   Google Scholar
• De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124(7):1626-36
   PubMed Web of Science ®Google Scholar
• Rolfe KJ, MacLean AB, Crow JC, et al. TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva. Br J Cancer 2003;89(12):2249-53
   Google Scholar
• Choschzick M1, Hantaredja W, Tennstedt P, et al. Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol 2011;30(5):497-504
   Google Scholar
• Regauer S, Reich O, Eberz B. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study. J Am Acad Dermatol 2014;71(4):698-707
   Google Scholar
• Mahner S, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 Study. J Natl Cancer Inst 2015;107(3):dju426
   Google Scholar
• Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986;68(6):733-40
   PubMed Web of Science ®Google Scholar
• Reade CJ, Eiriksson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol 2014;132(3):780-9
   Google Scholar
• Gaffney DK, Du Bois A, Narayan K, et al. Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study. Int J Gynecol Cancer 2009;19(1):163-7
   Google Scholar
• Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42(1):79-85
   PubMed Web of Science ®Google Scholar
• Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2000;48(4):1007-13
   Google Scholar
• Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev 2011(4):CD003752
   Google Scholar
• van Doorn HC, Ansink A, Verhaar-Langereis M, et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev 2006(3):CD003752
   Google Scholar
• Mak RH, Halasz LM, Tanaka CK, et al. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol Oncol 2011;120(1):101-7
   Google Scholar
• Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012;124(3):529-33
   PubMed Web of Science ®Google Scholar
• Tans L, Ansink AC, van Rooij PH, et al. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 2011;34(1):22-6
   Google Scholar
• Han SC, Kim DH, Higgins SA, et al. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2000;47(5):1235-44
   Google Scholar
• Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006;100(1):53-7
   PubMed Web of Science ®Google Scholar
• Raspagliesi F, Zanaboni F, Martinelli F, et al. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol Oncol 2014;25(1):22-9
   PubMed Web of Science ®Google Scholar
• Aragona AM, Cuneo N, Soderini AH, et al. Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study. Int J Gynecol Cancer 2012;22(7):1258-63
   Google Scholar
• Domingues AP, Mota F, Durão M, et al. Neoadjuvant chemotherapy in advanced vulvar cancer. Int J Gynecol Cancer 2010;20(2):294-8
   PubMed Web of Science ®Google Scholar
• Han SN, Vergote I, Amant F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. Int J Gynecol Cancer 2012;22(5):865-8
   Google Scholar
• Lupi G, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer 1996;77(8):1472-8
   Google Scholar
• Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group). Ann Oncol 2009;20(9):1511-16
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649-55
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370(8):734-43
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, Homesley HD, et al. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study. Gynecol Oncol 1986;23(3):358-63
   Google Scholar
• Muss HB, Bundy BN, Christopherson WA. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. Am J Clin Oncol 1989;12(2):142-4
   Google Scholar
• Wagenaar HC, Colombo N, Vergote I, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol 2001;81(3):348-54
   Google Scholar
• Cormio G, Loizzi V, Gissi F, et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology 2009;77(5):281-4
   PubMed Web of Science ®Google Scholar
• Pinto AP, Schlecht NF, Pintos J, et al. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol 2004;92(3):856-65
   Google Scholar
• Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995;85(5 Pt 1):709-15
   Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32):4294-301
   PubMed Web of Science ®Google Scholar
• Ferris RL, Martinez I, Sirianni N, et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer 2005;41(5):807-15
   PubMed Web of Science ®Google Scholar
• Pang E, Delic NC, Hong A, et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6 *I. Int J Radiat Oncol Biol Phys 2011;79(3):860-5
   Google Scholar
• Johnson GA, Mannel R, Khalifa M, et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol 1997;65(3):425-9
   Google Scholar
• Woelber L, Hess S, Bohlken H, et al. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. J Clin Pathol 2012;65(2):133-9
   Google Scholar
• Horowitz NS, Olawaiye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012;127(1):141-6
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;27(7):1069-74
   PubMed Web of Science ®Google Scholar
• Clere N, Bermont L, Fauconnet S, et al. The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Exp Cell Res 2007;313(15):3239-50
   Google Scholar
• Obermair A, Kohlberger P, Bancher-Todesca D, et al. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996;63(2):204-9
   PubMed Web of Science ®Google Scholar
• Bancher-Todesca D, Obermair A, Bilgi S, et al. Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 1997;64(3):496-500
   Google Scholar